[
  {
    "ts": null,
    "headline": "Bristol Myers Squibb: The Rerating Was Fast - The Proof Will Be Slow (Rating Downgrade)",
    "summary": "Bristol Myers Squibb (BMY) is up ~27% in 3 months; learn why itâs now a Hold, key Eliquis replacement risks, and dividend outlookâread now.",
    "url": "https://finnhub.io/api/news?id=d07a42e23ccc3568ad77753e17cc9ff8ef106c09521633c14ff2e8193106858b",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769255521,
      "headline": "Bristol Myers Squibb: The Rerating Was Fast - The Proof Will Be Slow (Rating Downgrade)",
      "id": 138246284,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2156325176/image_2156325176.jpg?io=getty-c-w1536",
      "related": "BMY",
      "source": "SeekingAlpha",
      "summary": "Bristol Myers Squibb (BMY) is up ~27% in 3 months; learn why itâs now a Hold, key Eliquis replacement risks, and dividend outlookâread now.",
      "url": "https://finnhub.io/api/news?id=d07a42e23ccc3568ad77753e17cc9ff8ef106c09521633c14ff2e8193106858b"
    }
  },
  {
    "ts": null,
    "headline": "Camzyos Trial Win and Microsoft AI Lung Program Might Change The Case For Investing In BMY",
    "summary": "In January 2026, Bristol-Myers Squibb announced positive Phase 3 SCOUT-HCM results for Camzyos in adolescents with symptomatic obstructive hypertrophic cardiomyopathy and unveiled an AI-focused collaboration with Microsoft to enhance early lung cancer detection across U.S. healthcare systems, including underserved communities. Together, these developments highlight how Bristol-Myers Squibb is pairing a maturing cardiovascular pipeline asset with digital oncology initiatives that could refine...",
    "url": "https://finnhub.io/api/news?id=32edbff4337ae7c7d74c6c8fa2ed91e4a3eeed900c5bd00e6b05fdbf54b40985",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769220864,
      "headline": "Camzyos Trial Win and Microsoft AI Lung Program Might Change The Case For Investing In BMY",
      "id": 138231122,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "In January 2026, Bristol-Myers Squibb announced positive Phase 3 SCOUT-HCM results for Camzyos in adolescents with symptomatic obstructive hypertrophic cardiomyopathy and unveiled an AI-focused collaboration with Microsoft to enhance early lung cancer detection across U.S. healthcare systems, including underserved communities. Together, these developments highlight how Bristol-Myers Squibb is pairing a maturing cardiovascular pipeline asset with digital oncology initiatives that could refine...",
      "url": "https://finnhub.io/api/news?id=32edbff4337ae7c7d74c6c8fa2ed91e4a3eeed900c5bd00e6b05fdbf54b40985"
    }
  }
]